

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Versi Ebrahim</u>			2. Issuer Name and Ticker or Trading Symbol <u>DMK PHARMACEUTICALS Corp [ DMK ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;"><b>CEO</b></p>		
(Last) (First) (Middle) <u>C/O DMK PHARMACEUTICALS CORPORATION</u> <u>11682 EL CAMINO REAL, SUITE 300</u>			3. Date of Earliest Transaction (Month/Day/Year) <u>09/15/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street) <u>SAN DIEGO CA 92130</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
<u>Common Stock</u>	<u>09/15/2023</u>		<u>C<sup>(1)</sup></u>		<u>729,200</u>	<u>A</u>	<u>\$0<sup>(1)</sup></u>	<u>906,394</u>	<u>I<sup>(2)</sup></u>	<u>By Versi Group LLC</u>
<u>Common Stock</u>								<u>8,745</u>	<u>D</u>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
<u>Series E Convertible Preferred Stock</u>	<u>(1)</u>	<u>09/15/2023</u>		<u>C<sup>(1)</sup></u>		<u>729.2</u>		<u>05/25/2023</u>	<u>(1)</u>	<u>Common Stock</u>	<u>729,200</u>	<u>\$0</u>	<u>1,212</u>	<u>I<sup>(2)</sup></u>	<u>By Versi Group LLC</u>

**Explanation of Responses:**

- On September 15, 2023, Versi Group, LLC converted 729.2 shares of Series E Convertible Preferred Stock ("Series E Preferred") into 729,200 shares of Common Stock, pursuant to the terms of the Series E Preferred. Each share of Series E Preferred is convertible into 1,000 shares of Common Stock at the election of the reporting person, subject to certain beneficial ownership limitations. The Series E Preferred has no expiration date.
- The reported shares are owned directly by Versi Group, LLC, of which the reporting person is the manager and a member. The reporting person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interests therein.

/s/ David J. Marguglio, as  
Attorney-in-Fact for Ebrahim 09/19/2023  
Versi

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.